OM241220C2000
- 0.05
- 0.000.00%
Outset Medical Newsroom
Stifel Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $6
TD Cowen Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $3
RBC Capital Maintains Outset Medical(OM.US) With Hold Rating, Maintains Target Price $3
BTIG Maintains Outset Medical(OM.US) With Buy Rating, Maintains Target Price $4
TD Cowen Maintains Outset Medical(OM.US) With Buy Rating, Cuts Target Price to $3
Outset Medical's Strong Q3 Performance and Strategic Expansion Justifies Buy Rating
RBC Capital Downgrades Outset Medical(OM.US) to Hold Rating, Cuts Target Price to $3
RBC Capital Remains a Hold on Outset Medical (OM)
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)
Outset Medical Price Target Cut to $3.00/Share From $6.00 by RBC Capital
Outset Medical Analyst Ratings
TD Cowen Maintains Buy on Outset Medical, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM), Rani Therapeutics Holdings (RANI) and Charles River Labs (CRL)
RBC Capital Reaffirms Their Hold Rating on Outset Medical (OM)
RBC Downgrades Outset Medical to Sector Perform From Outperform, Cuts Price Target to $3 From $6
Outset Medical: Resilient Performance and Strategic Initiatives Justify Buy Rating
Outset Medical up 15% Following Upgrade From RBC Capital Markets
Outset Medical Analyst Ratings
RBC Upgrades Outset Medical to Outperform From Sector Perform, Raises Price Target to $6 From $5
Analysts' Top Healthcare Picks: Outset Medical (OM), Cytokinetics (CYTK)